Image

Study on the Visual Condition in Parkinson's Disease

Study on the Visual Condition in Parkinson's Disease

Recruiting
18 years and older
All
Phase N/A

Overview

Non motor symptoms and signs in Parkinson's disease (PD) also include a series of visual deficits; deepening these aspects could be useful for a better management of symptoms, to standardize a specific protocol for the issues related to vision and also to understand how these aspects are important for the understanding of the mechanisms underlying the PD.

Description

In Parkinson's disease (PD) several non-motor signs and symptoms already occur in the early stages of the disease; the symptoms are diverse and these also involve visual difficulties which commonly affect the majority of patients and which gradually worsen the quality of life.
The most common malfunction produced by PD is the dysfunction of dopaminergic pathways that may be responsible for a series of visual deficits too:
  • decreased visual acuity and decreased sensibility to light and color,
  • strabismus and forms of sensory and eye movement dysfunctions,
  • eyelid dysfunctions and dry eye syndrome
Moreover, in patients affected by PD, typical retinal features were discovered for the first time in 2004 by the use of OCT (Optical Coherence Tomography) such as:
  • the reduction of the retinal nerve fiber layer (RNFL)
  • a typical thinning of the macular thickness, even if with different results. In the follow-up of the PD, these retinal features, verifiable by the use of OCT, could be considered as a marker of the pathology.
For these reasons it may be useful:
  • quantify in an objective manner how much the visual aspects affect the overall deterioration of the quality of life in patients with PD
  • demonstrate the validity of a specific and integrated outpatient diagnostic protocol for the study of visual and ophthalmological disorders in patients with PD
  • demonstrate the diagnostic role of early changes in macular thickness and of the optic disc in subjects suffering from PD using the OCT
  • establish orthoptic evidence in patients with PD

Eligibility

Inclusion Criteria:
 
  • Patients aged 18 years
  • Patients affected by Parkinson's disease (PD) according to the diagnostic criteria of the United Kingdom Brain Bank, in the ON phase of their usual treatment
  • Hoehn-Yahr Stage from 1 to 3
  • Signature of the Informed Consent and of the privacy form
Exclusion Criteria:
  • Patients with symptoms and signs compatible with atypical parkinsonism
  • PD patients treated with antagonist drugs for central dopaminergic receptors (first and second generation antipsychotics) in the last 6 months before enrollment
  • Patients suffering from other neurological diseases
  • Patients with evident cognitive impairment (MMSE <24/30)
  • Patients with manifest eye movement disorders prior to the diagnosis of PD.
  • Patients with daltonism
  • Patients with amblyopia
  • Patients suffering from high anisometropia
  • Patients suffering from advanced cataracts
  • Patients suffering from glaucoma
  • Patients suffering from maculopathy
  • Patients suffering from pathologies of the optic nerve
  • Patients with severe visual field deficits
  • Patients with refractive defects above 5 diopters

Study details
    Parkinson's Disease
    Parkinson's Disease

NCT03743467

Neuromed IRCCS

19 February 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team


Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.